The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.